Investment and expected profit

1) Systemic infections (Sepsis): For lacking investigations - rest of preclinial investigations, clinical phase I (toxicity profile) and clinical phase II (proof of concept) a sum of 4 Million € is lacking.

2) Non-systemic (local) infections: For lacking investigations - rest of preclinial investigations, clinical phase I (toxicity profile) an clinical phase II (proof of concept) a sum of 600 thousand € is lacking.

3) After proof of concept: For the single indications following annual turnover can be expected (worldwide):

  • Sepsis: 3 – 4 billion € (from extrapolation of the withdrawn drug Xigris®, which was applicable only for a few percent of patients and generated an annual turnover of 192 Million $).
  • Local bacterial infections: This is a huge market and annual turnovers can be estimated to lie higher than 10 Billion €
  • Influenza (H3N2, seasonal flu , H1N1 ‚swine flu‘ and others):  Turnover should be in the range of 300 – 800 Million €, from extrapolation of drug Tamiflu®
  • Human immune deficiency virus (HIV): Turnover in the range of 8-10 Billion €, from extrapolation of data from the  HAART-medicament
  • Hepatitis B (HepB):  No therapeutics exists. Worldwide over 350 Million humans are chronically infected (danger of liver cirrhosis and liver cancer). According estimates , the turnover should lie in the range of some hundet Million €.
  • Human Papillome Virus (HPV): No therapeuticum exist. The anti-HIV medicament Lopinavir®  is under investigation. No estimate possible.